Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Dec 1, 2011
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different dyes, specifically Brilliant Blue G (BBG) and Indocyanine Green (ICG), can help surgeons during a procedure to remove the Internal Limiting Membrane (ILM) in patients with Macular Edema. These dyes are used to make it easier and safer to see and remove the ILM, which can help improve vision. While ICG is commonly used, it has some safety concerns, so the researchers are looking to see if BBG or other dyes can provide similar benefits without the risks.
To participate in this trial, you need to be over 18 years old and have not had any similar eye surgery in the last six months. Pregnant individuals or those under 18 cannot join. If you decide to participate, you will undergo a surgery where one of the dyes will be used to assist the surgeon. This study is currently recruiting participants, and it aims to improve the safety and effectiveness of eye surgeries involving the ILM.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 Years of age
- • No other chromovitrectomy in previous 6 months
- • Only one of three vitaly dyes used intraoperatively (BBG, ICG or TB)
- Exclusion Criteria:
- • Previous chromovitrectomy during last 6 months
- • Pregnant patients
- • Patients under 18 years of age
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Linz, , Austria
St. Gallen, Sg, Switzerland
Winterthur, , Switzerland
Paradiso, Ti, Switzerland
Patients applied
Trial Officials
Paul B Henrich, MD
Principal Investigator
Oftacentro, Lugano-Paradiso, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials